Oct 30 : S&P Global Ratings on Friday revised its outlook on Meta Platforms to negative, citing significant uncertainty around capital spending and free operating cash flow.
Source: Reuters
S&P Global Ratings announced on Friday, Oct. 30, that it altered its perspective on Meta Platforms. The agency determined that substantial capital spending creates too much financial uncertainty for the business at this time. Additionally, weaker projections for free operating cash flow contributed directly to the credit evaluation downgrade.
Oct 30 : S&P Global Ratings on Friday revised its outlook on Meta Platforms to negative, citing significant uncertainty around capital spending and free operating cash flow.
Source: Reuters
Escalating investments in artificial intelligence have begun to strain the tech giant's balance sheet, prompting credit agencies to flag rising financial risks. Wall Street reacted swiftly to these liquidity concerns, sending the company's equity into its steepest monthly downturn in four years. To offset heavy operational drains, management is now executing a massive multibillion-dollar financing plan across public equity markets.
Investors are bidding up shares of Inovio Pharmaceuticals during current trading hours. Market participants are monitoring the biotechnology firm closely as its equity experiences substantial upward movement. Additional information regarding the specific drivers behind this market activity remains limited at this time.
The chipmaker's projected fourth-quarter revenue of $15 billion to $16 billion missed Wall Street targets, prompting a severe selloff that also hit tech peers like Nvidia. Rising hardware costs fueled by the artificial intelligence boom have pressured client IT budgets, causing wider operational challenges. Despite the steep single-day valuation drop, long-term federal holdings in the company retain overall gains for the calendar year.